N4 Pharma Plc

N4 Pharma (N4P)

Company name:N4 Pharma Plc
EPIC:N4PTrading Currency:GBX
Market Sector:AMQ1ISIN:GB00BYW8QM32
Market Segment:ASQ1Share Type:DE
WWW Address:https://www.n4pharma.com/investorsDescription:ORD 0.4P
 Price Price Change [%] Bid Offer Open High Low Volume
 8.35 images.advfn.com/imagesnew/2/gb/down -0.25 [-2.91] 8.20 8.50 8.45 8.45 8.35 531,583
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 13.03 156.08 0.00 -0.96 - - - 15.50 - 4.65

N4 Pharma Key Figures

(at previous day's close)
Market Cap.13.03m
Shares In Issue156.08m
Prev. Close8.60
PE Ratio- 
Dividend Yield-%
EPS - basic-0.96p
Dividend PS-p
Dividend Cover- 
Cash Flow PS-0.88p
Return On Equity (ROE)-35.68%
Operating Margin-%
PEG Factor- 
EPS Growth Rate-10.34%
Dividends PS Growth Rate-%
Net Debt-3.39m
Gross Gearing4.42%
Quick Assets3.83m
Net Working Capital3.66m
Intangibles / Fixed Assets-%
Turnover PS-p
Pre-Tax Profit PS-1.00p
Retained Profit PS-0.84p
Cash PS2.28p
Net Cash PS2.17p
Net Tangible Asset Value PS *2.34p
Net Asset Value PS2.34p
Spread0.30 (3.53%) 

N4 Pharma Balance Sheet


Share Price Performance

Sample Period HighLow
1 week8.878.20
4 weeks10.258.15
12 weeks10.407.70
1 year15.504.65

Share Price Chart (5 years)

N4 Pharma Historic Returns

Period OpenChange%Open Avg.Avg. Daily Vol [m]Total Vol [m]VWAP
1 week8.60-0.25-2.918.200.558.49
4 weeks8.300.050.608.150.909.05
12 weeks8.55-0.20-2.347.701.338.64
26 weeks8.150.202.457.302.129.65
1 year4.903.4570.414.653.209.37
3 years8.95-0.60-6.702.151.768.08
5 years6.751.6023.702.151.559.43

N4 Pharma Key Management Ratios

N4 Pharma Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio- 
PE Ratio- 
Tobin's Q Ratio 5.33 
Tobin's Q Ratio (excl. intangibles)5.33 
Dividend Yield-%
Market-to-Book Ratio3.56 
Price-to-Pre-Tax Profit PS-8.32 
Price-to-Retained Profit PS-9.99 
Price-to-Cash Flow PS-9.45 
Price-to-Sales PS- 
Price-to-Net Tangible Asset Value PS3.56 
Price-to-Cash PS3.67 
Net Working Capital PS2.34 
Price Pct to Working Capital PS3.56%
Earnings Yield-%
Average PE- 
Years in average- 
PE to PE average-%

N4 Pharma Financial Ratios

(Leverage Ratios)
Debt Ratio-%
Debt-to-Equity Ratio- 
Debt-to-Equity Ratio (excl. Intgbl)- 
Debt-to-Equity Market Value- 
Net Gearing-88.50%
Net Gearing (excl. Intangibles)-88.50%
Gross Gearing4.42%
Gross Gearing (excl. Intangibles)4.42%
Gearing Under 1 Year4.42%
Gearing Under 1 Year (excl. Intgbl)4.42%
(Liquidity Ratios)
Net Working Capital to Total Assets95.58%
Current Ratio22.63 
Quick Ratio (Acid Test)22.63 
Liquidity Ratio21.03 
Cash & Equiv/Current Assets92.92%
(Solvency Ratios)
Enterprise Value9.48m
CFO/Attributable Profit- 
Total Debt/Equity Market Value0.01 
Total Debt/Sales- 
Total Debt/Pre-Tax Profit-0.11 
Total Debt0.17m
Total Debt/Net Current Assets0.05%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth-10.07%
5 yr Compound Earnings Growth-%
10 yr Compound Earnings Growth-%
Earn drops > 5% in 10yrs2 
Beta (60-Mnth)Beta (36-Mnth)

N4 Pharma Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE)-42.83%
Return On Assets (ROA)-53.35%
Net Profit Margin-%
Assets Turnover- 
Return On Equity (ROE)-35.68%
Return On Investment (ROI)-56.19%
Dividend Payout Ratio-%
Plowback Ratio100.00%
Growth from Plowback Ratio-%
Net Income Of Revenues-%
(Asset Utilisation Multiples)
Shareholders Equity Turnover- 
Fixed Assets Turnover- 
Current Assets Turnover- 
Net Working Capital Turnover 
Inventory Turnover- 
(Other Operating Ratios)
Total Assets-to-Sales- 
Debt Collection Period-Days

N4 Pharma Dividends

Sorry No Data Available

N4 Pharma Fundamentals

 31 Dec 2017 (GBP)31 Dec 2018 (GBP)31 Dec 2019 (GBP)31 Dec 2020 (GBP)
pre tax profit-1.93--1.39--0.95--1.57-m
attributable profit-1.84--1.18--0.88--1.30-m
retained profit-1.84--1.18--0.88--1.30-m
eps - basic (p)-1.26 -1.32 -0.87 -0.96 
eps - diluted (p)-1.24 -1.30 -0.87 -0.94 
dividends per share- - - - 

N4 Pharma Balance Sheet

 31 Dec 2017 (GBP)31 Dec 2018 (GBP)31 Dec 2019 (GBP)31 Dec 2020 (GBP)
 31 Dec 2017 (GBP)31 Dec 2018 (GBP)31 Dec 2019 (GBP)31 Dec 2020 (GBP)
fixed assets fixed assets--%--%--%--%m
intangibles intangibles--%--%--%--%m
fixed investments fixed investments--%--%--%--%m
current assets - other current assets - other--%--%--%--%m
stocks stocks--%--%--%--%m
debtors debtors0.139.10%0.2825.88%0.109.32%0.277.08%m
cash & securities cash & securities1.3390.90%0.7974.12%0.9790.68%3.5692.92%m
creditors - short creditors - short0.1812.28%0.1917.77%0.087.29%0.174.42%m
creditors - long creditors - long--%--%--%--%m
creditors - other creditors - other--%--%--%--%m
subordinated loans subordinated loans--%--%--%--%m
insurance funds insurance funds--%--%--%--%m
ord cap, reserves ord cap, reserves1.2887.72%0.8882.23%0.9992.71%3.6695.58%m
prefs, minorities prefs, minorities--%--%--%--%m
NAV Basic- - - - 
NAV Diluted- - - - 

N4 Pharma Cash Flow Statement

31 Dec 2017 (GBP)31 Dec 2018 (GBP)31 Dec 2019 (GBP)31 Dec 2020 (GBP)
Operating CF-0.95-1.34-0.81-1.38m
Pre-Financing CF-0.55-1.32-0.81-1.38m
Retained CF1.31-0.530.172.59m

N4 Pharma Brokers

Broker infomation is not available for this class of stock.
ADVFN Advertorial
Your Recent History
N4 Pharma
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210724 11:24:51